Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Proposes Unilateral Generic Drug Label Changes, Signaling End To Liability Shield

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.

Advertisement

Related Content

US FDA May Ask Congress For More Resources After Withdrawing Generic Label Reg
Will Antimicrobial Breakpoint Changes Signal Shift To Online Labeling Updates?
US FDA Gets A New Lawyer: Rebecca Wood Named Chief Counsel
US FDA Gets A New Lawyer: Rebecca Wood Named Chief Counsel
Gottlieb Q&A: Sen. Murray Wants To Know About Generic Labeling Rule
Gottlieb Q&A: Sen. Murray Wants To Know About Generic Labeling Rule
FDA Label Decisions On Paxil Don't Deter Verdict Against GSK In Suicide Case
FDA Label Decisions On Paxil Don't Deter Verdict Against GSK In Suicide Case
FDA May Drop Generic Liability Shield, Allow ANDA Manufacturers To Change Labels
Generic Firms Get Supreme Shield From Product Liability, But Court Hints At Reg Change

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel